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Abstract. The development of functional blood and lym-
phatic vessels requires spatio-temporal coordination of 
the production and release of growth factors such as vas-
cular endothelial growth factors (VEGFs). VEGF family 
proteins are produced in multiple isoforms with distinct 
biological properties and bind to three types of VEGF 
receptors. A VEGF-A splice variant, VEGF-A165b, has 
recently been isolated from kidney epithelial cells. This 
variant is identical to VEGF-A165 except for the last six 
amino acids encoded by an alternative exon. VEGF-A165b 
and VEGF-A165 bind VEGF receptors 1 and 2 with similar 
affinity. VEGF-A165b elicits drastically reduced activity 
in angiogenesis assays and even counteracts signaling by 
VEGF-A165. VEGF-A165b weakly binds to heparan sulfate 
and does not interact with neuropilin-1, a coreceptor for 
VEGF receptor 2. To determine the molecular basis for 
altered signaling by VEGF-A165b we measured VEGF re-
ceptor 2 and ERK kinase activity in endothelial cells in 
culture. VEGF-A165 induced strong and sustained activa-
tion of VEGF receptor 2 and ERK-1 and -2, while activa-
tion by VEGF-A165b was only weak and transient. Taken 
together these data show that VEGF-A165b has attenuated 
signaling potential through VEGF receptor 2 defining 
this new member of the VEGF family as a partial recep-
tor agonist.
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Introduction
Angiogenesis, the formation of new blood vessels from 
preexisting ones, is a complex and tightly regulated pro-
cess. The development of fully functional vessels requires 
spatio-temporal coordination of the production, release 
and deposition in the extracellular matrix (ECM) of sev-
eral growth factors such as vascular endothelial growth 
factors (VEGFs), angiopoietins, transforming growth 
factor-β, fibroblast growth factor and platelet-derived 
growth factor (PDGF) by many cell types (reviewed in 
[1–3]). This process is counterbalanced by angiogenesis 
inhibitors such as ECM-derived polypeptides or specific 
inhibitory molecules like PEDF [4, 5]. Impaired vessel 
function is associated with many pathologies, for instance 
in atherosclerosis [6], diabetic retinopathy [7, 8], arthri-
tis [9], malignant cell growth [10–12], neurodegenera-
tive disease such as amyotrophic lateral sclerosis (ALS) 
[10, 13] and in preeclampsia, a placental insufficiency 
observed in some patients in the late stage of pregnancy 
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[14]. These disorders arise from mutation or impaired 
expression of various signaling molecules regulating 
angiogenesis, in particular of angiogenic growth factors 
such as VEGFs and their receptors that directly operate 
on endothelial cells.
VEGFs regulate physiological and pathological angio-
genesis and belong to a gene family that includes VEGF-
A, -B, -C, -D [3], placenta growth factor (PlGF) [15], 
orf virus-encoded VEGF-like proteins called VEGF-E 
[16–18] and a series of snake venoms collectively called 
VEGF-F [19–22]. VEGF family growth factors form 
cysteine cross-linked dimers folded into a cysteine knot 
structure [23]. All mammalian VEGFs are produced in 
multiple isoforms upon alternative splicing and proteo-
lytic processing giving rise to a plethora of functionally 
divergent proteins [24, 25]. Although structurally very 
similar, the different VEGFs display distinct properties 
and bind to specific subtypes of VEGF receptors. VEGFs 
are produced by normal and transformed cells upon ex-
posure to hypoxia [26, 27] and promote endothelial cell 
growth, migration and survival, but also regulate blood 
vessel permeability and vasodilation (reviewed in [10]). 
The importance of VEGF in vascular development has 
been documented in knockout mice where disruption of 
a single allele of the VEGF-A gene leads to embryonic 
lethality [28, 29]. Even subtle changes in VEGF expres-
sion during fetal development [28, 30], a block in the ex-
pression of a particular VEGF-A splice variant [31] or 
disruption of one allele of the gene encoding VEGFR-2 
result in abnormal blood vessel formation and are em-
bryonic lethal [33]. VEGF is also important for tumor 
growth; blocking VEGF with antibodies, soluble receptor 
or inhibiting VEGF receptor kinase activity have shown 
promising clinical results in tumor therapy [10].
In mammals VEGF-A is expressed in many variants upon 
alternative splicing of a single precursor mRNA. Four ma-
jor splice variants, VEGF-A121, VEGF-A165, VEGF-A189 
and VEGF-A206 have been described [34, 35]. The longer 
isoforms show binding affinity to the ECM, particularly 
to heparan sulfate glycosaminoglycans (HSPG), while 
VEGF-A121 is a soluble, acidic polypeptide that does not 
interact with HSPG [35]. The longer versions of VEGF-A 
bind to additional receptors such as neuropilin-1 and -2, 
which play a role in cell adhesion and in nerve and ves-
sel guidance [36–38]. Increased activation of VEGFR-2 
in the presence of heparan sulfate (HS) and neuropilin-
1 or -2 has been observed for VEGF-A165, the isoform 
most prominently expressed in mammals [37–39]. The 
most basic VEGF variant, VEGF-A189, is sequestered in 
the ECM and shows no biological activity unless mobi-
lized by heparinases, while VEGF-A206 is proteolytically 
cleaved and released from the ECM by metalloprotein-
ases. Recently, new VEGF-A splice variants have been 
described which carry an alternative C terminus encoded 
by exon 9 instead of exon 8 [40, 41]. The best character-
ized member of these proteins is VEGF165b which was 
isolated from kidney epithelial cells. This protein showed 
anti-angiogenic properties counteracting VEGF-A165 in 
vitro and in vivo.
VEGFs signal through cell surface receptor tyrosine ki-
nases related to the PDGF receptor family. VEGF-A binds 
to both VEGF receptor 1 (VEGFR-1) and -2 (VEGFR-
2) [3, 10], while PlGF and VEGF-B exclusively bind to 
VEGFR-1 [42–44].VEGF-C and VEGF-D are specific 
ligands for VEGFR-2 and VEGFR-3, which regulate 
both blood and lymphatic vessel development [45].Viral 
VEGF-Es and some snake venom VEGF-F variants ex-
clusively activate VEGFR-2 [18–20].
Here we study the biological activity of VEGF-A165b in 
which the C-terminal domain encoded by exon 8 was 
replaced by an exon 9-encoded sequence. This protein 
binds VEGF receptors with the same affinity as VEGF-
A165, shows reduced binding to HS, does not bind neuro-
pilin-1 and displays altered signaling properties through 
VEGFR-2 and ERK kinases.
Materials and methods
Materials. VEGF-A165, VEGF-A165b, VEGF-A121, VEGF-
E and PlGF were produced in Pichia pastoris using the 
pPICZαA expression system (Invitrogen, San Diego, 
CA, USA) [46]. Myelin basic protein (MBP) and hepa-
rin (H-1027) were from Sigma (St. Louis, MO, USA). 
Bovine serum albumin (BSA) was obtained from Pro-
mega (Madison, WI, USA). ERK antibodies were K-23 
for ERK-1 (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) pan-ERK (E17120, Transduction Laboratories, 
BD Biosciences, Franklin Lakes, NJ, USA), phospho-
ERK (Cell Signaling, Cambridge, MA, USA), and rabbit 
polyclonal anti-ERK-2 (F135, a generous gift from Dr. 
D. Fabbro, Novartis, Basel, Switzerland). Rabbit anti-
mouse antibody and alkaline phosphatase conjugated 
species-specific antibodies were from Southern Biotech 
(Birmingham, AL, USA). Monoclonal anti-VEGF anti-
body MAB293 and MAB3045 (specific for the exon 9 
variant), polyclonal rabbit anti-VEGF AB293 and poly-
clonal anti-Tie-2 antibodies were from R&D Systems Inc. 
(Minneapolis, MN, USA). Protein A Sepharose CL-4B 
was from GE Healthcare and [γ-32P]ATP was from ICN 
(Costa Mesa, CA, USA). Antibodies against VEGFR-2 
and pY1175 were from Santa Cruz (A3) and Cell Signal-
ing, respectively.
Tissue culture. Human umbilical vein endothelial cells 
(HUVE cells, Promocell, Heidelberg, Germany) were 
used up to passage 8. Cells were grown in endothelial 
cell growth medium (ECGM) containing the supplement 
C-39210 (Promocell). They were starved overnight in en-
dothelial cell basal medium (ECBM) supplemented with 
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0.1% fetal bovine serum (FBS, Invitrogen, Gibco-BRL). 
Porcine aortic endothelial cells (PAE cells) overexpress-
ing VEGFR-1 or VEGFR-2 or VEGFR-2 together with 
neuropilin-1 [47] were maintained in Ham’s F12 medium 
containing 10% FBS. BAEC cells were grown in DMEM 
with 10% donor calf serum.
Cloning and expression of VEGFs. The methylotrophic 
yeast Pichia pastoris was used to express all VEGF iso-
forms. Our constructs were derived from the canine iso-
form of VEGF-A, which is shorter by one amino acid than 
the human isoforms [48]. The exon 8 encoded sequence 
(Cys Asp Lys Pro Arg Arg) was replaced by the sequence 
Ser Leu Thr Arg Lys Asp encoded by human exon 9. All 
expression vectors were constructed by the PCR sub-
cloning method [49] with the QuickChange site-directed 
mutagenesis kit (Stratagene, La Jolla, CA, USA) using 
pPICZαAVEGF-A165, a vector for expression of VEGF-
A165 in Pichia pastoris [48], as template. The following 
primers were used in the first PCR reaction: VEGF-A165b 
primer 1: 5′-GCGACTGGTTCCAATTG ACAAG-3′, 
VEGF-A165b primer 2: 5′-GATGATGATGATGTCGACT-
CATCAGTCTTTCCTGGTGAGAGATCTGCAAG-
TAGTTCGTTTAACTCAAG-3′, VEGF-A159 primer 1: 5′-
GCGACTGGTTCCAATTGACAAG-3′ and VEGF-A159 
primer 2: 5′-GATGATGATGATGGTCGAATCATCTG-
CAAGTACGTTCGTTTAACTC-3′. The constructs were 
linearized with SacI and transferred into Pichia pastoris 
strain X-33 by electroporation (EasyselectTM Pichia Ex-
pression Kit, Invitrogen). Clones were selected for protein 
expression (EasyselectTM Pichia Expression Kit, Invit-
rogen). The proteins were produced in a 3.7 l fermenter 
(Bioengineering, Wald, Switzerland) as described [46].
Purification of VEGF-A165b and VEGF-A159. Proteins 
were affinity purified with an ÄKTAprimeTM system (GE 
Healthcare). Cell-free medium was collected from yeast 
cultures, sterile filtered through 0.45-μm MFTM membrane 
filters (Millipore, Billerica, MA, USA) and concentrated 
to 200 ml by ultrafiltration (Schleicher & Schuell GmbH, 
Dassel, Germany). Buffer was exchanged with binding 
buffer (20 mM sodium phosphate, pH 7.4, 0.5 M NaCl 
and 10 mM imidazole) and loaded onto a 50-ml Ni2+-
NTA column (GE Healthcare) equilibrated with binding 
buffer. The material was eluted by gradually increasing 
the imidazole concentration to 500 mM. The peak frac-
tions were analyzed by SDS-PAGE, pooled, concentrated 
using a YM 10 ultrafiltration membrane (Millipore) and 
dialyzed overnight at 4 °C against PBS.
Radioiodination and cell binding assays. 125Iodine la-
beling of recombinant VEGF-A165 was performed with 
the IODO-GEN method according to the Pierce proto-
col (Pierce, Rockford, IL, USA). Briefly, 0.5 mCi Na125I 
(IMS-30, GE Healthcare) was activated for 6 min at 
room temperature (RT) by incubation in a tube coated 
with 50 μg iodogen and mixed with a solution contain-
ing 10 μg VEGF-A165 for 9 min at RT. The reaction was 
stopped with 1 mM DTT and the iodinated protein was 
separated from free iodine on a PD10 gel filtration column 
(GE Healthcare) equilibrated with 0.5% BSA, 1 mM cit-
ric acid in PBS. The specific radioactivity of VEGF-A165 
was 62 000 cpm/ng. PAE cells expressing VEGFR-1 or 
VEGFR-2 or VEGFR-2 together with neuropilin-1 were 
grown overnight to subconfluency in 24-well tissue cul-
ture plates and incubated for 4 h at 4 °C with 0.1 nM 125I-
labeled VEGF-A165 with or without the indicated amount 
of cold competitor. Each data point was determined in 
triplicate. Unbound radioactive protein was washed off 
with MEM-HBS, 25 mM HEPES, with or without L-
glutamine (Amimed, Allschwil, Switzerland) containing 
0.25% BSA. Cells were then lysed in 200 μl 1 M NaOH 
and radioactivity determined in a Beckman γ counter.
In vivo chicken embryo chorioallantoic membrane 
(CAM) assay and histological analysis of CAMs. Pro-
tein (1 μg) was applied to a 0.5% methylcellulose carrier 
placed onto the CAM of shell-free grown chicken embryos 
(Lohman LSL strain, Animalco, Staufen, Switzerland) at 
embryonic day 8. Angiogenesis was monitored for up to 
4 days after sample application under a stereomicroscope 
and pictures were taken. A solution of 20% Lipovenös 
(Fresenius Kabi, Stans, Switzerland) was injected into the 
CAM immediately before photographing to improve the 
contrast. For histological analysis, CAMs were fixed in 
3.5% formaldehyde at 4 °C. Areas to be analyzed were 
cut out and washed in PBS for 30 min at 4 °C. Samples 
were incubated for 30 min at RT in 0.85% NaCl, rinsed 
twice in 50% EtOH in 0.85% NaCl, then in 70% EtOH 
in PBS for 20 min at RT and embedded in paraffin. Sec-
tions were deparaffinized in xylene and stained with he-
matoxylin (Medite AG, Nunningen, Switzerland) and eo-
sin (Chroma-Gesellschaft, Münster, Germany). Average 
pixel intensities of digitized pictures were quantified with 
ImageJ software (NIH, Bethesda, MD, USA).
In vivo chamber implant angiogenesis assay. Sterile 
tissue chambers made of perfluoro-alkoxy-Teflon® were 
filled with 500 μl molten 0.8% w/v agar containing 
20 U/ml heparin (Novo Nordisk A/S, Bagsvaerd, Den-
mark) with or without growth factor (46 or 92 nM) and 
implanted aseptically into female mice (FVB) (Charles 
River Laboratories, les Oncins, France). Four days after 
implantation, chambers were recovered from the animals 
and the vascularized tissue that had formed around each 
implant was removed and weighed. Tissue samples were 
homogenized in RIPA buffer (50 mM Tris-HCl, 121 mM 
NaCl, 1 mM EDTA, 6 mM EGTA, 1% NP-40, 20 mM 
NaF, 1 mM Pefabloc SC, 1 mM Na3VO4). Samples were 
then centrifuged for 1 h at 7000 rpm. The supernatant 
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was filtered using a 0.45-µm syringe filter (Acrodisc® 
GF, Gelman Sciences, Ann Arbor, MI, USA) to avoid 
fat contamination. The amount of hemoglobin present 
in the filtrate was determined spectrophotometrically at 
540 nm using a Drabkin reagent kit (Sigma). For Tie-2 
determination Nunc maxisorb 96-well plates were coated 
overnight at 4 °C with the capture anti-Tie-2 antibody 
(Upstate Inc., Charlottesville, VA, USA) at a concentra-
tion of 2 μg/ml. Wells were washed three times with Tris 
phosphate-buffered saline (TPBS) and blocked by incu-
bating with 3% Top-Block (Juro, Lucerne, Switzerland) 
for 2 h. Wells were then washed three times with TPBS 
and protein lysates were added for 2 h. After washing, a 
complex of anti-Tie-2 antibody (R&D Systems) and al-
kaline phosphatase conjugated anti-goat antibody (Pierce 
Biotechnology) was applied for 1 h at RT. After washing 
three times with TPBS, Tie-2 antibody complexes were 
detected by incubating with p-nitrophenyl phosphate (4-
NPP) (Sigma) and the absorbance was determined in an 
ELISA reader at 405 nm. Recombinant human extracellu-
lar domain of Tie-2 fused to the constant region of human 
IgG1 dissolved in RIPA buffer was used as standard.
Heparin affinity chromatography. VEGF was applied 
to a 1 ml HiTrap heparin HP column (GE Healthcare) 
equilibrated with varying salt concentrations in 20 mM 
Tris (pH 7). VEGF was eluted with a linear salt gradi-
ent reaching a final concentration of 1.2 M and column 
fractions were monitored on an ÄKTA prime system (GE 
Healthcare) operated at a flow rate of 1 ml/min.
Neuropilin-1 binding in ELISA. Nunc microtiter plates 
were coated overnight at 4 °C with 2.8 μg/ml recombi-
nant neuropilin-1 (R&D Systems). Plates were washed 
twice with PBS and blocked in PBS containing 2% BSA 
for 1 h at 37 °C. Unspecific binding was determined on 
duplicate plates treated with 2% BSA in PBS. After wash-
ing, the different VEGF isoforms were added to the wells 
at the indicated concentrations, followed by a 1 h incu-
bation at 37 °C. After washing with PBS, bound VEGF 
was detected using a mixture of monoclonal anti-VEGF 
(R&D Systems) and alkaline phosphatase conjugated 
anti-mouse antibody. Plates were rinsed three times with 
Tris-buffered saline (20 mM Tris/HCl, pH 7.5, 150 mM 
NaCl, TBS) and alkaline phosphatase activity was deter-
mined colorimetrically with 4-NPP, absorbance at 410 nm 
was quantified in an ELISA reader.
Immunoprecipitation and in vitro immune complex 
kinase assays. VEGFR-2 activity was determined in 
Western blots using a phospho-specific antibody directed 
against Y1175 of VEGFR-2 (Cell Signaling). ERK-1 and 
-2 activity was determined in immune complex kinase 
assays with MBP as substrate. Cells were plated in 6 cm 
plates and grown in Ham’s F12 or ECGM for 24 h and 
starved overnight in medium plus 0.1% FBS. Cells were 
stimulated at 37 °C, washed once with cold PBS con-
taining 100 μM Na3VO4, and lysed in 500 μl lysis buf-
fer. Lysates were cleared by centrifugation at 13 000 rpm 
and incubated for 2 h with anti-ERK-1 and anti-ERK-2 
polyclonal antibody. Protein A Sepharose (60 μl) were 
added to each sample for an additional hour at 4 °C and 
the beads were washed once with TNET (50 mM Tris, 
pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100), 
TNE (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA), 
and H2O and equilibrated in kinase buffer (20 mM HEPES 
pH 8, 20 mM MgCl2, 2 mM MnCl2 and 1 mM DTT). Im-
munoprecipitated ERK-1 and -2 were incubated in kinase 
buffer containing 5 μCi [γ-32P]ATP and 10 μg MBP for 
15 min at 30 °C. Kinase reactions were stopped by the 
addition of sample buffer and the samples were separated 
by SDS-PAGE, transferred to PVDF membranes and 
exposed to X-Ray film. PVDF membranes were further 
analyzed by Western blotting for quantification of ERK-1 
and -2. Unspecific binding was blocked with 3% gelatin 
in TBS. Mouse anti-pan-ERK was used as first antibody, 
alkaline phosphatase conjugated anti-mouse as secondary 
antibody. Blots were developed with a mixture of NBT 
(nitro-blue tetrazolium chloride, Sigma) and BCIP (5-
bromo-4-chloro-3′-indolylphosphate p-toluidine, Sigma) 
diluted in development buffer (100 mM Tris, pH 9.5, 
100 mM NaCl, 5 mM MgCl2). Quantification of the data 
was performed with ImageQuant software (Molecular 
Dynamics, GE Healthcare). The films were scanned and 
the ratio of the intensities of the bands corresponding to 
the pY1175 and the MBP signal, respectively, were cor-
rected for the intensity of the bands reflecting the total 
amount of VEGFR-2 and ERK-1 and -2, respectively.
Results
VEGF production and purification. All VEGFs were 
produced in the yeast Pichia pastoris [48] as described 
before and purified via an N-terminal His6 tag on Ni2+-
NTA chelating Sepharose. The identity of the proteins 
was confirmed by Western blot analysis and by Edman 
sequencing (data not shown). To investigate whether the 
sequence encoded by exon 8 of VEGF-A165 has a spe-
cific function in receptor activation, we also produced a 
recombinant variant, VEGF-A159, that lacks the last six 
amino acids encoded by either exon 8 or 9.
VEGF-A165b and VEGF-A159 bind to VEGFR-1 and 
VEGFR-2 with the same affinity as VEGF-A165. 
Binding of VEGF-A variants to VEGF receptors was 
determined on PAE cells expressing either VEGFR-1 
or VEGFR-2. Figure 1a shows that VEGF-A165b and 
VEGF-A159 displaced 125I-labeled VEGF-A165 from cells 
expressing VEGFR-2 with the same efficiency as VEGF-
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A165. Consistent with this observation, PlGF, which does 
not bind VEGFR-2, did not block VEGF-A165 binding to 
VEGFR-2. Binding was also determined on PAE cells ex-
pressing VEGFR-1, where VEGF-A165, VEGF-A165b and 
VEGF-A159, but not VEGF-E, blocked VEGF-A165 bind-
ing (Fig. 1b). These results demonstrate that the sequence 
encoded by exon 8 is not required for binding to VEGF 
receptors 1 and 2 and that the exon 9 variant showed iden-
tical binding to VEGF receptors as the exon 8 isoform.
In vivo angiogenesis. A simple experimental system to 
qualitatively evaluate the angiogenic potential of growth 
factors in vivo is the chicken CAM. Samples (1 μg) of 
each VEGF variant were applied to the CAM of an 8-day-
old chicken embryo and vascularization in the area of ap-
plication evaluated 48 h later. Compared with PBS con-
trols (average pixel intensity ± SD, 138 ± 13), where no 
alteration of the vascular network was seen, VEGF-A165 
induced a network of microvessels giving the CAM in 
this area a reddish color (average pixel intensity 149 ± 27, 
Fig. 2a). Average pixel intensities for VEGF-A165b and 
VEGF-A159 were 138 ± 17 and 138 ± 14, respectively. 
Histological examination of hematoxylin and eosin-
stained paraffin sections shows that capillaries are only 
located in the chorionic epithelium and that the stroma 
is avascular in PBS controls. VEGF-A165-treated CAMs 
displayed highly vascularized stroma with a large number 
of erythrocytes, while CAMs treated with VEGF-A165b 
or VEGF-A159 showed only few vessels (Fig. 2b). These 
results suggest that the C-terminal domain encoded by 
exon 8 is required for full biological activity of VEGF-
A165. The exact role that exon 8 plays in VEGF-mediated 
vascularization remains at present unknown.
We next implanted a chamber containing an agarose/
heparin matrix loaded with VEGF under the skin of a 
mouse. As shown in Figure 3, VEGF-A165 and VEGF-
A159 strongly induced angiogenesis in this animal model. 
VEGF-A165b and VEGF121 had only a marginal effect on 
vessel invasion in this assay. Interestingly, VEGF-A165b 
Figure 1. VEGF-A165, VEGF-A165b and VEGF-A159 bind VEGF 
receptors on endothelial cells with the same affinity. 125I-labeled 
VEGF-A165 (0.1 nM) was competed with increasing amounts of 
competitor protein for 4 h at 4 °C on PAE cells expressing VEGFR-
2 (a) or VEGFR-1 (b). Values are means ± SD, n = 3.
Figure 2. CAM assay. (a) CAMs were photographed 48 h after ap-
plication of either PBS or 1 μg VEGF-A165, VEGF-A165b or VEGF-
A159, respectively. Compared with controls and exon 8 mutant pro-
teins, where the vascular network remained unchanged, VEGF-A165 
promoted highly vascularized CAMs. The dashed circle shows 
where ligand was applied. (b) Hematoxylin and eosin-stained par-
affin sections of CAMs.
a
b
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antagonized VEGF-A165 when both proteins were simul-
taneously added in equimolar amounts reminiscent of ear-
lier described data [41], while VEGF-A159 and VEGF121 
were not inhibitory. These data indicate that VEGF165b is 
a partial receptor agonist with normal binding capacity 
for VEGFR-1 and -2 but reduced or qualitatively altered 
signaling potential.
VEGF-A165b and VEGF-A159 show reduced binding to 
HS and do not bind to neuropilin-1. VEGF-A165 inter-
acts with HSPG proteoglycans such as glypicans [50–53]. 
This interaction has been proposed to be mediated by the 
exon 7-encoded domain [54]. Our initial attempts to purify 
VEGF-A165b by heparin-affinity chromatography were 
not successful, and we therefore constructed expression 
vectors encoding N-terminally His6 tagged proteins. Hep-
arin binding of all VEGF-A variants was quantitatively 
determined on a HiTrap heparin HP column equilibrated 
with 20 mM Tris and 0.15 M NaCl at pH 7. The bound 
material was eluted by applying a linear NaCl gradient 
from 0.15 to 1.2 M. Of the VEGF-A165, 55% was bound 
to the heparin column and eluted at a salt concentration of 
0.4 M, while VEGF-A121, the most acidic VEGF-A splice 
variant, did not bind heparin at all. At 0.15 M salt VEGF-
A165b and VEGF-A159 only weakly interacted with heparin 
with 14% and 21%, respectively, of the material bound to 
the column. In the absence of NaCl, all proteins contain-
ing the exon 7, but lacking the exon 8 sequence, weakly 
bound to the column, while VEGF121 did not bind hepa-
rin at all (data not shown). These data show that VEGF-
A lacking exon 8 shows drastically reduced affinity for 
heparin, suggesting that the C-terminal exon 8-encoded 
sequence is essential for interaction with HS. HS binding 
does not, therefore, solely depend on sequences encoded 
by exon 7 as described before.
The longer isoforms of VEGF family proteins also bind 
to neuropilins, a class of cell surface receptors involved in 
many biological processes [55]. This interaction has been 
shown to be mediated by the exon 7 domain of VEGF-A 
[56]. We next determined binding of the various VEGF-A 
isoforms to recombinant neuropilin-1. As shown in Fig-
ure 4a, VEGF-A165 bound to neuropilin-1, while the vari-
ants lacking exon 8 showed no binding. Similarly, VEGF-
A165, but not VEGF-A165b, VEGF-A159 and VEGF-A121, 
Figure 3. In vivo growth factor implant angiogenesis model. Po-
rous chambers containing PBS or VEGF-A (46 nM or 92 nM) in 
0.5 ml 0.8% agar containing 20 U/ml heparin were implanted sub-
cutaneously into the flank of a mouse. The angiogenic response was 
quantified by measuring (a) the weight, (b) the blood content, and 
(c) Tie-2 expression in the tissue that grows around the implant. 
Measurements were performed 4 days after implantation. Values 
are mean ± SEM, n = 6. The dashed horizontal line indicates the 
background level obtained when only PBS buffer was added. (d) 
Representative photographs of two chamber implants, PBS control, 
and VEGF-A165-treated sample.
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efficiently blocked binding of VEGF-A165 to neuropilin-1 
in competitive ELISA (Fig. 4b). These data were con-
firmed on PAE cells expressing VEGFR-2 together with 
neuropilin-1. As shown in Figure 4c, only exon 8 contain-
ing VEGF-A completely competed binding of VEGF165. 
Our data therefore suggest that sequences encoded by 
exon 7 are not sufficient for HS and neuropilin-1 binding 
to VEGF-A and thus reveal a role for the exon 8 sequence 
in these interactions.
VEGF-A165b shows delayed and attenuated signal 
output through VEGFR-2. We next assessed the signal-
ing properties of VEGF-A165 and VEGF-A165b using a 
phospho-specific antibody against pY1175 of VEGFR-2 
as shown in Figure 5a. Receptor stimulation by VEGF-
A165b was delayed, less robust and more transient than 
with VEGF-A165. One of the primary signaling pathways 
activated by VEGFR-2 is signaling via MAP kinases such 
as ERK-1 and -2 that regulate cell migration, survival, 
mitogenesis and cell differentiation. Earlier results sug-
gest that the extent and the kinetics with which recep-
tor tyrosine kinases activate MAP family kinases are of 
pivotal importance for the biological output elicited by a 
particular ligand [57–59]. We, therefore, studied the time 
course of ERK-1 and -2 activation in two types of endo-
thelial cells derived from pig aorta (PAEC) and bovine 
aorta (BAEC). We found robust and sustained activation 
of ERK-1 and -2 by VEGF-A165, while VEGF-A165b pro-
moted only weak and blunted activation (Fig. 5b). The 
predominant MAP kinase activated in endothelial cells 
was ERK-2. In cells treated with VEGF-A165 ERK-2 ac-
tivity was two- to threefold lower than in controls treated 
for 15 min with fetal calf serum (lanes F in Figure 5b) and 
was up to tenfold lower in cells treated with VEGF-A165b 
(Fig. 5b). A quantification of a series of experiments is 
given in Table 1. In all experiments VEGF-A165b showed 
significantly lower activity at all time points. From these 
data, we conclude that the C-terminal domain of VEGF-
A encoded by exon 8 determines the kinetics and the 
strength of signal output by VEGFR-2.
Discussion
The discovery of new VEGF-A splice variants by Bates 
and coworkers has raised interesting questions concern-
ing the role of the C-terminal domain encoded by exon 8 
of VEGF-A165 in receptor activation. The biological activ-
ity of this splice variant was initially described in tumor 
cells expressing VEGF-A165b, which showed drastically 
reduced malignancy in vivo when compared with VEGF-
A165 expressing cells [40, 41]. Putative exon 9 variants of 
VEGF-A can be deduced from the mouse, human, dog, 
bovine, monkey, quail and zebrafish DNA sequence [41] 
(and our own unpublished work). The exon 9 encoded 
sequence is not conserved among these species, while 
the rest of the protein sequence is highly conserved. This 
indicates that the specific biological function of VEGF-
A165b might predominantly derive from the absence of 
exon 8 and not from the acquisition of new functional-
ities encoded by exon 9. The phenotype of VEGF-A159, a 
mutant that was made to assess whether exon 9 is directly 
Figure 4. VEGF-A mutants lacking the exon 8 encoded sequence 
do not bind neuropilin-1. (a) Various VEGF-A isoforms were added 
in increasing concentrations to recombinant neuropilin-1 immobi-
lized on ELISA plates. Values are means ± SD, n = 3. (b) Competi-
tion of 125I-labeled VEGF-A165 binding to recombinant neuropilin-1 
immobilized on ELISA plates by various VEGF-A isoforms. Values 
are means ± SD, n = 3. (c) Competition of 125I-labeled VEGF-A165 
binding to PAE cells expressing VEGFR-2 and neuropilin-1 by 
various VEGF-A isoforms, values are means ± SD, n = 3.
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responsible for the biological activity of VEGF-A165b, or 
whether the absence of exon 8 was sufficient, was, how-
ever, not clear. In some assays, VEGF-A159 was similar to 
VEGF-A165b, in others it behaved like VEGF-A165. Re-
placing exon 8 by exon 9 resulted therefore in a more 
drastic phenotype than exon 8 deletion. Without detailed 
structural information for VEGF-A165b such data are dif-
ficult to interpret. So far only the structures of a C-termi-
nally truncated form of VEGF-A [60] and of the exon 7 
and 8 encoded heparin binding domain have been solved 
[61]. This latter NMR structure shows that cysteine 146 
forms an intramolecular disulfide bond with cysteine 
160, restricting the flexibility of this domain and stabiliz-
Figure 5. Time course of VEGFR-2 and ERK kinase activation. (a) Activation of VEGFR-2 was determined with a phospho-specific 
antibody recognizing pY1175 in cells stimulated with 50 ng/ml VEGF-A. Top panel, Western blot treated with p1175Y antibody; middle 
panel, Western blot showing the total amount of immunoprecipitated VEGFR-2; graph, data quantification (relative activity corrected for 
total amount of protein). (b) Time course of ERK-1 and -2 activation in cells stimulated with 50 ng/ml VEGF-A. a) and b), ERK activity 
determined in PAE cells expressing VEGFR-2, c) and d), similar experiment performed with BAEC cells. a) autoradiograph of an in vitro 
ERK-1 and -2 MBP phosphorylation assay; b) Western blot showing the total amount of immunoprecipitated ERK-1 and -2 used for the 
phosphorylation assay; c) Western blot showing ERK-2 activity determined with a phospho-specific antibody, d) Western blot showing 
total amount of ERK-2 determined with pan ERK-1/2 antibody. Lanes marked with F in c) and d) show activity of cells stimulated for 
15 min. with 10% FBS. Lysates prepared from the same amount of cells were loaded on each lane of the gels. Representative experiments 
are shown, statistical analysis from several experiments for ERK activation is given in Table 1.
Table 1. Kinase activity of ERK-1/-2 determined by MBP phos-
phorylation assays after stimulation with 50 ng/ml VEGF-A.a
ERK activity % activity SD (n = 3)
15 min 38 12
30 min 27  2
60 min 29  6
120 min 42  2
180 min 24 18
a Shown are the relative activities of VEGF-A165b compared 
with VEGF-A165 determined in HUVE and PAE cells expressing 
VEGFR-2. Activity of VEGF-A165 at each time point was arbitrarily 
set to 100% (p < 0.09 in all series).
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ing a patch of basic amino acids exposed on the surface 
of this protein. The functional significance of this disul-
fide bond is further documented by a VEGF-A mutant in 
which cysteine 146 was changed to a serine residue [62] 
and which had reduced activity. Taken together, our data 
show that the sequence encoded by exon 8 is part of the 
heparin and neuropilin-1 binding domains and/or is man-
datory for their proper folding. VEGF-A mutants lack-
ing cysteine 160 may assume a more flexible structure, 
resulting in reduced affinity for HSPG and preventing 
binding to neuropilin-1. Additional mutagenesis of exon 
8 will help to elucidate the exact role that this domain 
plays in VEGF-A mediated receptor activation.
All VEGF-A variants lacking exon 8 studied here bound 
VEGF receptors 1 and 2 with the same affinity as VEGF-
A165. On the other hand, mutants lacking exon 8 only 
weakly bound HS and did not bind to neuropilin-1 at all. 
Expression in endothelial cells of neuropilin-1, a plexin 
family protein that also interacts with semaphorins and 
plays an essential role in both neural guidance and ves-
sel development, has been shown to enhance binding of 
VEGF-A165 to VEGFR-2 [37, 53, 63]. This was attributed 
to the b1b2 domain of neuropilin-1 that interacts with the 
exon 7 and 8 encoded C terminus of VEGF-A165 [64]. The 
importance of neuropilin-1 for the development of func-
tional vessels is well documented in knockout animals 
[65]. Using in vivo angiogenesis animal models we show 
that VEGF-A165b has reduced biological activity and even 
inhibits angiogenic signaling when used together with 
VEGF-A165 .
VEGF-A165b also elicited significantly weaker signal 
output through VEGFR-2 and ERK kinases. This further 
documents that binding to HSPG and neuropilin-1 is not 
only required for the deposition and storage of VEGF-
A165 in the ECM and on neuropilin-1-expressing cells, but 
that these interactions have also a direct impact on recep-
tor signaling. VEGF-A165 leads to robust and sustained 
activation of VEGFR-2, while signaling via VEGFR-2 by 
the exon 9 variant is weak, shows delayed kinetics, and 
is only transient. Such differences might result from the 
distinct structure of ligand/receptor complexes, and sug-
gest that only VEGF-A165 is capable of fully activating the 
receptor and its downstream signaling pathways. Co-liga-
tion of VEGFR-2 with HSPG and/or neuropilin-1, result-
ing in delayed receptor desensitization by phosphatases 
and attenuated receptor degradation similar to recently 
published work on HSPG/VEGFR-2 complexes is a pos-
sible explanation for this phenomenon [66].
Coordinated expression of soluble and ECM-bound 
VEGF-A are indispensable for the development of func-
tional vascular networks. Neuropilin-1-expressing cells 
might further support this process by sequestering VEGF-
A, thereby contributing to the ordered deposition of this 
protein in the vascular bed. Based on our data we propose 
that HSPGs and/or neuropilin-1 fulfill an additional role 
by directly modulating VEGF-mediated receptor activa-
tion. Exon 8 VEGF-A splice variants show features that 
are typical for partial receptor agonists; they bind VEGF 
receptors with identical affinity as fully functional li-
gands yet elicit attenuated signal output. The biological 
role that VEGF-A isoforms lacking exon 8 play in vivo 
during vessel development remains at present unclear and 
must be addressed in transgenic animals.
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